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was signiflcsntly smaller I” H vs N hearts (14+4% and 45+4%, p=.OOOO). Conclusion: with Killip Class II or Ill. The Table shows the medications administered during the first 24 
This study shows that hypothermic therapy initiated late during ischemia and continuing hours of presentation and at discharge. 
for several hours of rep significantly improves reflow and reduces macroscopic zones of Conclusion: Despite available data showing the benefit of proven medical therapies for 
no-reflow and hemorrhage in this model, suggesting protection of the microvasculature the treatment of patients with acute coronary syndromes and congestive head failure, 
by reducing repeiiusion injury. As reflow is a predictor of outcome, this intervention may except for aspirin, many of these medications continue to be underutilized especially in 
have important clinical implications. high-risk patients. 
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1171-106 Early Short-Term Use of Atorvastatin and Pravastatin in 
Patients With Non-ST Elevation Acute Coronary 
Syndrome: Changes of Hemostatic Parameters 
Ekaterlna Pokrovskaya, Nikolai Vaulln, Oleg Averkov. Natalia Slavina. Nikolai 
Gratsiansky. Institute of Physico-Chemical Medicine, Moskva, Russian Federation 
Background. Whether statins rapidly (in 1-2 weeks) and similarly affect hemostatic 
parameters in patients with non-ST elevation acute coronary syndrome (NSTEACS) is 
unknown. 
Methods: Ninety aspirin and heparin treated patients with NSTEACS were randomized 
~24 hours from pain onset to open pravastatin 40 mglday (n=31), atorvastatin 10 mgiday 
(n=30) or atorvastatin 40 mglday (n=29). Plasma thrombin-antithrombin complex (TAT), 
prothrombin fragments I+2 (Fl+2). D-dimer and van Willebrand factor (vWF) were mea- 
sured by ELISA at baseline, on days 7, 14. Results were compared with data from con- 
trols (n=l8) of another randomized study on similarly treated patients. 
Results: In all treatment groups levels of low-density lipoprotein cholesterol (LDLC) were 
lowered by days 7 (pcO,Ol) and 14 (p<O,Ol vs. baseline and for both atolvastatin groups 
vs. day 7). In pravastatin group levels of TAT and Fl+2 decreased, while vWF level 
increased (table). In atorvastatin groups levels of TAT and F 1+2 increased while level of 
vWF decreased Contrary to pravastatin group changes in atorvastatin groups more 
resembled those in controls not receiving lipid lowering drugs. There was slight negative 
correlation between changes of LDLC and TAT levels. No consistent changes of D-dimer 
occurred. 
Conclusion : Early use of pravastatin and atorvastatin in patients with NSTEACS was 
associated with divergent changes of some hemostatic paramebxs. 
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1171-108 Superior Efficacy of Low Molecular Weight Heparin 
Versus Unfractionated Heparin in Acute Coronary 
Syndromes Without ST Elevation 
Thlbaud Dam& Anissa Bouzamondo, Gilles Montalescot, Philippe Lechat, Pitie 
Saleptriere Hospital, Pans, France 
Background: In acute coronary syndrome without ST elevation (ACS), there is conflict- 
ing evidence regarding the efficacy of low molecular weight heparin (LMWH) versus 
unfractionnated heparin (UFH). We performed a meta-analysis of trials comparing the 
class of LMWH versus UFH on the combined criteria of Death or Myocardial Infarction (D 
or MI) I” ACS. 
Methods: Randomised trials were identified using Medline and Cochrane database. 
Pooled Relative Risk was calculated with published data. Seven trials Including 15998 
patients fulfilled the inclusion criteria (Gudinkel, FRIC, FRISC, FRISC II, ESSENCE, TIMI 
11 B, FRAXIS). 
Results: M&a-analysis of five trials (Gurfinkel, FRIC. ESSENCE, TIMI llB, FRAXIS), 
including 12169 patients demonstrated superiority of LMWH versus UFH to reduce D or 
Ml during the acute phase (6-8days) [RR=0.83; 95%Cl(O.70-0.99); p=O.O42]. Heteroge- 
neity test was non significant (p=O.47) but subgroup analysis according lo the type of 
LMWH, showed that amplitute of benefit was highest with enoxaparin IRRz0.78; (0.62. 
0.96); p=O.O2] compared to dalteparin [R&1.09; (0.65.1.82)] or nadroparin (RRz0.92; 
(0.62-1.37)]. M&-analysis of long term LMWH administration trials (FRIC, FRISC, 
FRISCII, TIMIllB, FRAXIS) showed that no additional benefit [RR=O.SE; (0.82-1.16); 
p=O.78] was obtained when considering only events occurring after the acute phase. 
During the acute phase, no significant difference was observed for major bleedings 
[RR=l.Ol; (0.81.1.26)]. However minor bleedings were significantly Increased by LMWH 
[RR=l.96; (1.65.2,61); piO.OOl]. Prolonged administration significantly increased the 
major bleeding rate [RR=2.27; (1.63-3.18); p<O.OOl)]. Conclusion: When considering 
ischemlc events during the first week of ACS, there is a signlflcant favorable class effect 
for LMWH compared to UFH. However, prolonged LMWH treatment increases major 
bleedings without significant additional benefit on ischemic events. 
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1171-107 In-Hospital and Discharge Utilization of Medications in 
Patients With and Without Heart Failure Presenting With 
Acute Coronary Syndromes: Insights From the 
PURSUIT Study 
Monvadi B. Srichai, Robert A. Harrington, Judith S. Hochman, Penny L. Houghtaling, 
Eric J. Velazquez, A. Michael Lincoff, Maarten L. Sirnoons, Wael A. Jaber, The 
Cleveland Clinic Foundation, Cleveland, OH, Duke University Medical Center, Durham, 
NC 
Background: Several medical interventions have been proven in the last two decades to 
improve the prognosis of patients with coronary artery disease and congestive heart fail- 
ure. We evaluated the rate of utilization of proven medical therapies in major national and 
international medical centers participating in the PURSUIT trial. 
Methods: We analyzed 9419 patients who were enrolled in the PURSUIT trial between 
November 1995 and January 1997. We assessed the medication usage at the time of 
randomization and at discharge for patients presenting with and without symptoms of 
hearl failure on presentation. 
Results: 8558 patients presented with Killlp class I and 861 patients were diagnosed 
1171-109 Adherence to Secondary Prevention Therapies 
Following Acute Coronary Syndromes: One-Year 
Results From the Canadian Acute Coronary Syndrome 
Registry 
Andrew T. Yan, Shaun G. Goodman, Mary Tan, David Fitch&t, Chi-Ming Chow, Anatoly 
Langer, Canadian ACS Registry Investigators, University of Toronto and Canadian Heart 
Research Centre. Toronto. ON, Canada 
Background: Clinical trials have clearly established the role of effective pharmacothera- 
pies in the secondary prevention of acute coronary syndrome (ACS) However, there are 
limited data regarding the longer-term adherence to these therapies after discharge. 
Methods: The ACS Registry is a prospective Canadian observational study of 5312 
patients with suspected ACS from 51 centres I” 9 provinces. A final diagnosis of ACS 
was dstermined in 4627 patients (27% Q wave myocardial infarctjon, 31% non-Q myo- 
cardial infarction, 41% unstable angina). Discharge medication use was recorded by 
treating physicians. Follow-up medication use (determlned by standardized telephone 
interview) was available for 3844 one-year survivors (8.8% unavailable). We compared 
the rates of medication use at discharge and at 1 year. 
Results: Medication use in 3844 patients at discharge and at l-year follow-up were as 
follows: 
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Medication At discharge At 1 -year follow-up p value 
ASA 93% 83% <0.001 
Beta-blockers 77% 66% <O.OOl 
ACE inhibitors 56% 55% NS 
ARBs 3.3% 7.5% CO.001 
Lipld lowering agents 57% 68% <O.OOl 
The rates and trends for medication use were similar irrespective of the index discharge 
ACS diagnosis. 
Conclusions: While the use of acetylsalicylic acid (ASA) and beta-blockers was high at 
discharge, It declined significantly at l-year follow-up. In contrast, the use of angiotensin 
converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARES), and lipid low- 
erlng agents was sustained or increased. While the reasons for medication discontinua- 
tlon are unknown, there appears to be a significant opportunity to improve on the 
adherence to ewdence-based therapies. 
Reocclusion 
l-year deathlreinfarction 
1171-112 Incremental Cost-Effectiveness of Early and Long-Term 
Clopidogrel in Patients Undergoing Percutaneous 
Coronary Infarction in the CURE Trial: The PCI-CURE 
Economic Analysis 
Shamir R. Mehta, Willlam S. Weintraub, Bengt Jonsson, Andre Lamy. Elizabeth 
Mahoney, Peter Lindgren, Marcus Flather, Michel E. Bertrand, Feng Zhao, Susan 
Chrolavicius, Keith A. Fox, Salim Yusuf. McMaster University, Hamilton, ON, Canada 
1171-110 Lesion Characteristics Affect Thrombolysis in 
Myocardial Infarction Flow in Acute Myocardial 
Infarction: An Intravascular Ultrasound Study 
Jun-ichi Kotani. Gary S. Ming Marco T. Castagna, August0 D. Pichard. Lowell F. Satler, 
Ron Waksman, William 0. Suddath, Kenneth M. Kent, Neil J. Weissman, Washington 
Hospital Center, Washington, DC, Cardiovascular Research Foundation, New York, NY 
TIMI flow is a predictor of prognosis after acute myocardial infarction (AMI). Lesion mor- 
phology that determines TIMI flow has not been studied in detail, especially using intra- 
vascular ultrasound (IVUS). We therefore analyzed pre-intervention IVUS and 
angiography in 97 AMI pts who presented <72hrs from symptom onset. Forty-four pts 
(45.4%) received intravenous thrombolysis before IVUS. Because AMI lesions typically 
include thrombi, qualitative IVUS assessment focused on thrombus-related morpholo- 
gies: channels Into the plaque, bright-speckled elements, hypoechoic masses, and 
absence of an evacuated plaque cavity. Measurements included lesion and reference 
artery, lumen and plaque (artery-lumen) areas. Remodeling index was calculated as 
lesion/mean reference artenal area. Results: There were no significant differences in pt 
and vessel characteristics or history of thrombolysis among the 3 TIMI flow grade groups. 
IVUS results are shown in the table. Conclusion: TIMI flow in pts following AMI is related 
to plaque characteristics as determined by IVUS. In particular, evidence of thrombus 
(strongest in TIMI O/I and weakest in TIMI Ill), lesion length and positive remodeling, but 
not residual lumen, affect TIMI flow. 
Background:The Clopldogrel in Unstable Angina to Prevent Recurrent Events (CURE) 
trial Economic Analysis demonstrated the incremental cost-effectiveness of clopidogrel 
therapy in patients with non-ST segment elevation acute coronary syndrome (ACS). The 
purpose of the current analysis is to assess the cost-effectiveness of clopidogrel in the 
large subgroup (N=2658) of patients undergoing PCI in the CURE trial (PCI-CURE 
study). 
Methods: Cost effectiveness was assessed in 5 countries, including the United States, 
United Kingdom, France, Sweden and Canada based upon the results of the PCI-CURE 
study. We calculated the costs of hospitalization, medication and study drug based on 
resource utilization for all patients undergoing PCI in the CURE study. Unit costs were 
derived from both Medstat and Medicare, representing both insurance and governmental 
payment systems in the United States. Cost effectiveness was expressed as the cost per 
event avoided. 
Results: Data to date are available for Sweden and France. Patients in the clopldogrel 
arm have on average higher costs than patients treated with ASA alone, 9,947 Euros 
compared to 9,817 Euros in Sweden and 6,465 Euros compared to 8,213 Euros; in 
France. The net cost is 130 and 252 Euros; in the two countries. The additional cost is 
due to the cost of clopldogrel, which is partly offset by savings during the initial hospital- 
ization. The cost offset was 335 and 152 Euros in Sweden and France, respectively. 
Other costs were similar in both groups. Treatment with clopidogrel led to 0.038 avoided 
events (0.126 events in the ASA arm compared to 0.088 in the clopidogrel + ASA arm). 
This lead to a cost-effectiveness ratio of 3,421 Euroslevent avolded in Sweden and 6,632 
Euro&event avoided in France. 
TIMI-O/I TIMI-II TIMI-III P 
Conclusions: Clopidogrel therapy started acutely and continued for up to one year is 
highly cost-effective in patients wth ACS undergoing PCI. A full cost-effectiveness analy- 
sis pertaining to all 5 countries will be presented in detail. 
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1171-113 The Significance of Early ST-Segment Resolution After 
Treatment With Aspirin in Patients Assigned to Primary 
Angioplasty 
Shlomi Matetzky, Victor Guena. llan Goldenberg, Oren Agranat, Yedael Har-Zahav, Elio 
DiSegni, David Varon, Michael Eldar, Hanoch Hod, Heart Institute, Sheba Medical 
Center, Tel Hashomer, Israel, Hematology Institute. Sheba Medical Center, Tel 
Hashomer, Israel 
Background: Post thrombolysis, early resolution of ST-segment elevation (STm) pre- 
dicts restoration of TIMI Ill in the infarct-related artery (IRA) with a oositive oredictive 
value (PPV) of 70.80%. Post successful primary angioplasty (PCI) SflR is a surrogate 
of tissue level reoerfusion. Sl?R after treatment with asolrin in oatients with .Sfl mvo- 
1171-111 Is Female Gender Associated With Impaired Outcome 
After Successful Thrombolysis? Insights From the 
APRICOT Trial 
Hendrik-Jan Dicker, Peter C. Kievit, Marc A. Brouwer, Paul J.P. C. van den Bergh, Wim 
R. M. Aengevaeren, Gerrit Veen, Freek W. A. Verheugt, Free University Medical Center, 
Amsterdam, The Netherlands, Heartcenter. University Medical Center, Nijmegen, The 
Netherlands 
Background: Female gender is often believed to portend worse outcome after ST-eleva- 
tion myocardial infarction (Ml). Whether this is independently related to gender, or prima- 
rily due to clinical and angiographic differences at baseline is a matter of debate. 
Methods: Patients (n=452) had fibrinolysis for acute ST elevation Ml and an open infarct 
artery at coronary angiography performed within 48 hours. Patients had 3-month follow- 
up angiography and l-year clinical follow-up. 
Results: Of the 452 patients 75 (I 7%) were female. Women were older (59*11 vs. 56+9 
years, p < O.Ol), more often had a history of hypertension (39% vs. 22%, p < 0.01) and 
were more often smokers than men (73% vs. 63%, p=O.O8). Single vessel disease was 
more frequent among women: 69% vs. 54% (p=O.Ol). Baseline stenosis severity (CICA) 
was less severe: 54+14 vs. 5&t3 (p=O.O4). Table 1 shows clinical and angiographic out- 
come. Adjustment for baseline imbalances did not reveal an independent relatlonship 
with gender. 
Conclusions: Despite a less favorable clinical baseline risk-profile, l-year clinical out- 
come after successful fibrinolysis did not differ between men and women. A higher-risk 
angiographic baseline profile was not apparent. and 3-month reocclusion was similar to 
men. These findings challenge the often generalized association between gender and 
OutCOme, and warrant further exploration as to whether other mechanisms drive this rela- 
tionshio. 
cardial infarction (STEMI) has not been investigated, although if r&able may effect 
immediate clinical management. 
Methods: The study comprised 172 consecutive patients assigned to primary PCI for 
STEMI. Patients were treated with chewable aspirin and heparin and the sum of STf 
&STf) was assessed on admission and afterl0-15 minutes of each aspirin dose. The 
patients were urgently catheterized regardless of the changes in SST?. TIMI flow in the 
IRA was determined on the initial and final angiogram. ADP- and epinephrine- induced 
platelet aggregation was determined before catheterization. Patients were followed 
throughout hospitalization. 
Results: Early XSflR 270% was associated with a higher prevalence of patent IRA 
(TIMI 11-111) on initial angiography (94% vs 24%. p<O.Ol) and of TIMI Ill flow (36% vs 6% 
p<O.Ol). IST? resolution 250% was similarly associated with a higher rate of IRA 
patency and TIMI Ill flow (p-zO.01 for both), but with a lower PPV for patency (85% vs 
94%) and for TIMI III flow (32% vs 36%). Patients with (36 [21%]) and without (136 
[79%]) early ZSTTR 2 70% did not differ with respect to aspirin dose (333+89 vs 
313+7lmg, p=O.l3) and use of heparin (85% vs 78%. p=O.8) prior to catheterization. 
age, gender and risk factor distribution. but had lower epinaphrine-induced platelet 
aggiegation (40.4*12% vs 59.5&11%. p=O.O15). Despite similar prevalence of TIMI Ill 
flow at the completion of the PCI (85% vs 83%, p=O.9) patients with SflR had a lower 
incidence of death or CHF (7.8% vs 25.4%, p=O.O5), QMI (42% YS 73%, p-zO.01). lower 
peak CK (750*1071 vs 2389*1854, pcO.Ol), and better LVEF (47+12 vs 42+t 1, p=O.O4). 
Conclusions: In patients with STEMI undergoing primary PCI,ISTTR 270% after aspirin 
treatment is a reliable sign of IRA patency, but not of TIMI Ill flow, and predicts smaller 
myocardial damage and better in-hospital outcome. 
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Table I 
Women Man OR (95% Cl) 
20% 19% 1.10 (0.56-2.12) 
1 1% 11% 0.98 (0.40-2.29) 
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